PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that investigators will present data for the Phase 3 investigational agent CARBAVANCE® (meropenem-vaborbactam) on activity against newly discovered BKC-1 and FR-1 serine lactamases at the 26th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held April 9-12 in Amsterdam. Investigators will also present data for ORBACTIV® (oritavancin) activity tested against European staphylococcal clinical isolates, including those with reduced susceptibility to daptomycin, teicoplanin or vancomycin.
